Diquinol Disease Interactions

The use of iodoquinol is contraindicated in patients with hepatic damage. Iodoquinol is a halogenated 8-hydroxyquinolone that may have a prolonged effect in patients with liver dysfunction. High dosages of iodoquinol have been associated with optic neuritis, optic atrophy, and peripheral neuropathy.

The use of high dosages or prolonged therapy with iodoquinol has been associated with the development of peripheral neuropathy. Therapy with iodoquinol should be administered cautiously in patients with peripheral neuropathy.

The use of iodoquinol has been associated with optic neuritis and optic atrophy when given in high dosages for prolonged periods. Optic atrophy has been reported mostly in children treated for acrodermatitis enteropathica at daily dosages between 1300 to 3600 mg for up to two years. Visual deterioration may be irreversible. Therapy with iodoquinol should be administered cautiously in patients with or predisposed to visual defects. Some clinicians also recommend not using iodoquinol and related agents in pediatric patients under 12 years of age. Long-term therapy should be avoided in all patients.

Protein-bound serum iodine levels may be increased during treatment with iodoquinol and may, therefore, interfere with certain thyroid function tests. Therapy with iodoquinol should be administered cautiously to patients with thyroid disease.